HOME >> MEDICINE >> NEWS
Some positive findings in new study on cocaine exposed children

A study in the May 26 issue of the Journal of the American Medical Association (JAMA) suggests that prenatal cocaine exposure was not associated with lower full scale IQ scores, or verbal or performance IQ scores at age 4 years. However, the study also found that prenatal cocaine exposure was associated with specific cognitive impairments and a lower likelihood of an above average IQ, but that home environments could make a difference for better outcomes for some children.

"Cocaine readily crosses the placental and fetal brain barriers and has a direct effect on the developing fetal brain " the authors provide as background information in the article. The authors add that "a number of methodologically sound studies have found a relationship between fetal cocaine exposure and negative child developmental outcomes in the first years of life, although others have not."

In this study, Lynn T. Singer, Ph.D., from the Case Western Reserve University School of Medicine, and colleagues assessed the effects of prenatal cocaine exposure and the quality of the caregiving environment on cognitive outcomes. The participants included 376 children (190 cocaine-exposed and 186 non-exposed) from a high-risk population who were enrolled in a longitudinal study from birth (September 1994 June 1996). They were screened for drug exposure as infants, assessed at 6, 12 and 24 months of age and then tested at 4 years old for cognitive developments.

The researchers found that prenatal cocaine exposure was not related to lower full-scale IQ scores (cocaine exposed 80.7 vs. nonexposed 82.9), summary verbal (cocaine exposed 79.9 vs. nonexposed 81.9) or performance IQ measures (cocaine exposed 85.5 vs. nonexposed 87.5) at age 4 years. "However, there were specific effects of prenatal cocaine exposure on several subscales, with cocaine-exposed children having lower information, arithmetic, and object assembly scores than nonexposed children," the researchers report. "Pre
'"/>

Contact: George Stamatis
George.Stamatis@case.edu
216-368-3635
Case Western Reserve University
26-May-2004


Page: 1 2

Related medicine news :

1. Social development program in childhood aids in positive functioning as an adult
2. Prialt receives positive CHMP recommendation for intrathecal treatment of severe chronic pain
3. Study finds HER2-positive breast cancer invades organs due to fatal chemical attraction
4. Studies demonstrate positive data in treatment of hepatitis C
5. Emselex(R) receives positive CHMP opinion for the treatment of overactive bladder
6. Studies show ACTOS(R) (pioglitazone HCl) has positive effects on various components of dyslipidemia
7. Zengen reports positive phase I/II trial results of its peptide molecule for vaginal yeast infection
8. Dementia, sensory neuropathy in sub-Saharan HIV-positive patients
9. HIV-positive U.S. military personnel accidentally vaccinated against smallpox
10. Intensive diabetes management yields positive results, according to Pittsburgh project
11. Harmless virus associated with longer life for some HIV-positive men

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Some positive findings new study cocaine exposed children

(Date:10/22/2014)... (PRWEB) October 22, 2014 On Saturday, October ... its fourth annual family health and fitness fair ¡Vive tu ... physical activity and good nutrition for better health and wellness ... which is free and open to the public, will be ... Brownsville, from 9:00 am to 1:00 pm. , “¡Vive ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 For Dr. Iris ... make money; it’s an extension of her life’s mission. Her ... venture as the owner of FirstLight HomeCare, make it clear ... important to me that my work makes a difference in ... an entrepreneurial spirit, so after much research, I felt ready ...
(Date:10/22/2014)... The Louis W. Sullivan Institute ... distribute health information technology innovation to transform quality ... development of six key guiding principles of patient-centered ... These are an expansion of the Institute of ... is respectful of and responsive to individual patient ...
(Date:10/22/2014)... Best Cheap Hosting USA is among ... site has recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) ... from around the world. , “iPower is one of ... is providing various kinds of useful products for new ... offering excellent customer service and a number of features ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Lintelus, Inc., ... Sr. Vice President of Sales, will be speaking on ... Meetings Technology Expo on October 28, at the Holiday ... hosting a booth as well as a Tech Demo ... Meeting can create a more engaging event experience. , ...
Breaking Medicine News(10 mins):Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2
(Date:10/22/2014)... 22, 2014 Sanomedics International Holdings, Inc. (OTCQB: ... Global Research & Data Services, demand for thermometers is ... through 2018, as demand for more accurate digital thermometers ... the world,s largest market for thermometers, and one of ... Sanomedics International Holdings, Inc. Sanomedics International Holdings ...
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... and dermatology therapies. PV-10, its novel investigational drug for ... the potential for systemic side effects. Its oncology focus ... liver. Provectus has completed phase 2 trials of PV-10 ... as a topical treatment for atopic dermatitis and psoriasis. ...
(Date:10/22/2014)... LA JOLLA, Calif. , Oct. 22, ... RGLS ), a biopharmaceutical company leading ... targeting microRNAs, today announced that it has ... from an ongoing clinical study evaluating RG-101, ... for the treatment of hepatitis C virus ...
Breaking Medicine Technology:Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
Cached News: